Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
At least 171 measles cases confirmed in 9 states, CDC data shows - 2How a Middle East War Becomes a Retail Price Hike
- 3Audits of the Top Science fiction Movies This Year
- 4Kiev declares energy emergency after Russian attacks amid winter cold
- 5One third of Spanish pork export certificates blocked since swine fever outbreak, minister says
- Artemis II's moonbound toilet is working again to astronauts' relief after overnight fix
- Photos: Hundreds Gather at Bondi Beach After Deadly Attack
- Figure out How to Reveal Stowed away Open Record Rewards
- Who plays Moana in the live-action remake? What to know about Catherine Lagaʻaia.
- Astrophotographer captures rare footage of the Hubble Telescope crossing the sun (video)
- Novartis to build manufacturing hub in North Carolina, creating 700 jobs
- Clovis Unified students spend spring break traveling through China
- Trump says Cuba is 'ready to fall' after capture of Venezuela's Maduro
- Hezbollah claims right to respond to killing of top commander
